The company collaborates with its suppliers to address supply delays and disruptions amid global supply chain constraints. Finished ENROUTE NPS devices undergo ethylene oxide sterilization at a qualified supplier. The company holds a license agreement with Cordis for intellectual property related to the PRECISE carotid stent, requiring exclusive collaboration with Cordis or Confluent Medical Technologies, Inc. for the development, manufacture, and supply of licensed products. If Cordis or Confluent cannot supply the products, a third-party manufacturer may be engaged with Cordis's consent. Under a supply agreement with Cordis, Cordis developed and supplied the ENROUTE stent for trials and commercial sale through February 19, 2029, with ongoing negotiations to extend supply beyond that date. Cordis holds exclusive manufacturing and supply rights for the current ENROUTE stent generation during the agreement term. If Cordis is unable to supply, Confluent or a third-party manufacturer may provide the stent, while Cordis retains rights to supply as able. The supply agreement includes a minimum volume purchase commitment from July 2023 through February 2029, with pricing based on prior year volume.
Silk Road Medical Inc's Comment on Supply Chain
The company collaborates with its suppliers to address supply delays and disruptions amid global supply chain constraints. Finished ENROUTE NPS devices undergo ethylene oxide sterilization at a qualified supplier. The company holds a license agreement with Cordis for intellectual property related to the PRECISE carotid stent, requiring exclusive collaboration with Cordis or Confluent Medical Technologies, Inc. for the development, manufacture, and supply of licensed products. If Cordis or Confluent cannot supply the products, a third-party manufacturer may be engaged with Cordis's consent. Under a supply agreement with Cordis, Cordis developed and supplied the ENROUTE stent for trials and commercial sale through February 19, 2029, with ongoing negotiations to extend supply beyond that date. Cordis holds exclusive manufacturing and supply rights for the current ENROUTE stent generation during the agreement term. If Cordis is unable to supply, Confluent or a third-party manufacturer may provide the stent, while Cordis retains rights to supply as able. The supply agreement includes a minimum volume purchase commitment from July 2023 through February 2029, with pricing based on prior year volume.
Sources:
Silk Road Medical Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Silk Road Medical Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
